other organs and disease relapse rate. While LPSP is associated with elevation of titers of nonspecific autoantibodies and serum IgG4 levels, IDCP does not have definitive serologic autoimmune markers. All experts agreed that the clinical phenotypes associated with LPSP and IDCP should be nosologically distinguished; however, their terminology was controversial. While most experts agreed that the entities should be referred to as type 1 and type 2 AIP, respectively, others had concerns regarding use of the term 'autoimmune' to describe IDCP.
cluded diffuse lymphoplasmacytic infiltration, marked interstitial fibrosis, acinar atrophy and obliterative phlebitis of the pancreatic and portal veins. They called the condition lymphoplasmacytic sclerosing pancreatitis (LPSP) with cholangitis [2] . In 1995, Yoshida et al. [3] described a 68-year-old woman with steroid-responsive disease presenting with obstructive jaundice, a diffusely enlarged pancreas, an irregularly narrowed pancreatic duct, hypergammaglobulinemia and elevated autoantibody titers. Drawing parallels from the literature on autoimmune hepatitis, the authors coined the term 'autoimmune pancreatitis' (AIP) [3] to describe this clinical entity. In 2002, the Japan Pancreas Society proposed diagnostic criteria for AIP [4] based on the classic imaging and serologic findings; these were revised in 2006 [5] .
In 2001, Hamano et al. [6] reported from Japan that elevated serum IgG4 levels were highly specific and sensitive for the diagnosis of AIP. In 2003, Kamisawa et al. [7] suggested that AIP is a systemic disease, based on the findings that there is abundant infiltration of the pancreas and other involved organs with IgG4-positive plasma cells. These features were included in the Korean diagnostic criteria for AIP proposed in 2007 [8] . In 2008, Japanese and Korean societies agreed on Asian consensus criteria for the diagnosis of AIP [9] . Recently, a Japanese study based on a survey of 17 centers in Japan identified 563 patients with AIP in Japan [10] .
Meanwhile, reports from Europe and the USA have described unique histologic patterns in resected pancreata of patients with mass-forming, chronic, nonalcoholic pancreatitis, showing clinical and histopathologic features overlapping with those of Japanese patients. In the first European study published in 1997, Ectors et al. [11] described the histologic pattern of 'non-alcoholic duct destructive pancreatitis' in 12 cases of idiopathic chronic pancreatitis, a histologic pattern which was clearly distinguishable from that of alcoholic chronic pancreatitis. The authors noted similarity of the pancreatic histopathologic findings not only with those reported in association with ulcerative colitis by Ball et al. [12] from the Mayo Clinic in 1950, but also with pancreatic involvement seen in sclerosing cholangitis reported from Japan [2] , as noted above. Italian diagnostic criteria for AIP were reported in 2003 [13] and were based on the histologic hallmarks outlined in the article by Ectors et al. [11] .
In 2003, the Mayo Clinic group in the USA reported 35 cases of 'idiopathic chronic pancreatitis with lymphoplasmacytic infiltration, sometimes called autoimmune pancreatitis' [14] . They observed 2 distinct histologic patterns in these patients: (1) LPSP and (2) idiopathic ductcentric pancreatitis (IDCP). LPSP resembled Japanese descriptions of histology seen in AIP, and IDCP resembled the European descriptions of 'duct-destructive pancreatitis'. The authors noted an overlap between the histologic features of the 2 patterns. They did not speculate on the etiology of IDCP, but wondered if LPSP was of autoimmune etiology. In 2006, Mayo Clinic investigators outlined diagnostic criteria for AIP using clinical data from patients with histologically confirmed LPSP [15] .
In 2004, Zamboni et al. [16] described the histology of 62 patients with 'autoimmune pancreatitis' from Europe; the unifying histologic feature in all patients was a periductal lymphoplasmacytic infiltrate with periductal fibrosis without any of the features seen in alcoholic pancreatitis, namely ductal dilatation or irregularity, calculi or pseudocysts. As in the Mayo Clinic series, 2 groups of patients were distinguished on the basis of a histological criterion that was called a 'granulocytic epithelial lesion' (GEL). Interestingly, the 2 groups of patients also differed with regard to features such as gender, mean age and associated immune-related diseases.
Summary: 'AIP' has been extensively described in reports from Japan, Europe and the USA. Large series of 'AIP' reported from Japan have been based on a distinct clinical phenotype, with little emphasis on or need for histology to diagnose the disease. On the other hand, detailed descriptions of at least 2 histopathologic patterns in patients with nonalcoholic idiopathic chronic pancreatitis, namely LPSP or AIP without GELs and IDCP or AIP with GELs, have been reported from Europe and the USA. Both histopathologic patterns have been included under the term 'AIP', based on the presence of features common to both, namely periductal lymphoplasmacytic infiltration and peculiar periductal fibrosis. The European diagnostic criteria for AIP use the presence of GEL as a hallmark of AIP, while criteria from the USA are based on clinical features of LPSP. Not surprisingly, the clinical phenotypes associated with both these histopathologic patterns have been called AIP.
The Honolulu Consensus Conference on AIP
On 4 November, 2009, experts from Japan, Korea, Europe (UK, Germany, Sweden and Italy) and the USA met in Honolulu, Hawaii, to describe the entity of AIP as they recognized it. The experts included gastroenterologists, pathologists, radiologists and surgeons. The goals of the meeting were to (1) agree upon a clinical and histological definition of AIP, (2) determine if the descriptions of the disease from Japan, Europe and USA refer to 1 or more disease entities and (3) arrive at a consensus on diagnostic criteria for AIP. In this review, the deliberations of the expert panel regarding the first 2 questions are detailed. During the deliberations, which were in a question and answer format, the questions shown below were discussed. The document was subsequently revised by the participants. At the Honolulu Consensus Conference on AIP, preliminary data were presented from an international concordance study of 40 resected cases of chronic pancreatitis to determine if AIP can be distinguished from alcoholic and obstructive forms of chronic pancreatitis. This study is ongoing. While the interobserver variability was moderate for the group as a whole, data from the 5 most accurate reviewers demonstrated 91.2% sensitivity and 98% specificity. The kappa statistic for the 5 readers was 0.89, reflecting excellent interobserver agreement. These findings suggest the need for additional educational efforts to improve the overall performance among pathologists. Full results of this study will be published shortly.
Definition of AIP
Summary: The expert panel agreed that AIP has unique histopathologic features which allow it to be distinguished from other forms of chronic pancreatitis.
Question: Is There More than One Histopathologic Subtype of AIP? In the concordance study noted above, readers were asked to classify the histologic patterns seen in AIP as either LPSP or IDCP. The sensitivity and specificity among the top 5 readers was 84 and 76.4%, respectively, with a kappa of 0.59, reflecting moderate interobserver agreement. Some readers had not previously diagnosed both histologic patterns and chose not to subdivide AIP into LPSP and IDCP, underscoring the need for additional educational efforts to improve the overall performance among pathologists. LPSP (AIP without GELs) has 3 essential histologic features ( fig. 1 ) [14, 17] : (1) a lymphoplasmacytic infiltrate surrounding small interlobular pancreatic ducts that does not destroy the pancreatic ductal epithelium; (2) a swirling fibrosis centered around ducts and veins (storiform fibrosis; fig. 2 ) but most prominent in the peripancreatic adipose tissue, and (3) obliterative phlebitis, wherein the infiltrate surrounds and obliterates pan- fig. 4 ) [18, 19] .
IDCP (AIP with GELs) has a histologic pattern distinct from LPSP [2, 14, 17] , though it also shares some features with LPSP. Periductal lymphoplasmacytic infiltrate is seen in both forms of AIP. Diffuse inflammation and diffuse storiform fibrosis as well as obliterative phlebitis, which are characteristic of LPSP, are less prominent in IDCP ( fig. 5 ). The most distinctive feature of IDCP is the presence of GELs, seen in medium-sized and small ducts and also often in the acini ( fig. 6 ), changes that may lead to the destruction and obliteration of the duct lumen [14, 17] . The other distinctive feature is the scanty presence ( ! 10 cells/high-power field) or complete absence of IgG4-positive plasma cells on immunostaining.
Question: Do LPSP and IDCP Have Distinct Clinical Profiles? Data were presented from Europe and the USA, based on histologically confirmed cases of LPSP and IDCP, highlighting differences in the demography, clinical presentation, serology, involvement of other organs and disease relapse ( table 2 ) .
Summary:
The participants agreed that patients currently diagnosed with 'AIP' have 2 histopathologically distinct types of disease that are associated with distinct clinical profiles. Thus, it is possible that LPSP (AIP without GELs) and IDCP (AIP with GELs) are histopathologic correlates of 2 distinct forms of AIP. This question sparked a vigorous debate. The center of the controversy related to the use of the term 'autoimmune' for IDCP. The Japanese experts contended that there is strong evidence to suggest that LPSP is an autoimmune disorder [hypergammaglobulinemia, prevalence of autoantibodies (albeit nonspecific) and a steroid- responsive lymphoplasmacytic infiltrate], while IDCP lacks such evidence. They believed that because of the relative paucity of data concerning IDCP, it was premature to label it as an autoimmune disorder. They further noted that unlike LPSP, which is commonly associated with extrapancreatic manifestations, IDCP appears to occur in isolation, except for a potential association with inflammatory bowel disease, particularly ulcerative colitis.
Others contended that the 2 diseases had many similarities. The most common clinical presentation of both diseases is obstructive jaundice with a pancreatic enlargement/mass. However, in the AIP patients with LPSP (unlike in IDCP), obstructive jaundice is caused by the specific pathologic change, i.e. sclerosing cholangitis with similar pathological features to LPSP. The few pancreatograms from IDCP cases that were shown during the meeting were not distinguishable from those seen in LPSP. Also, IDCP is also associated with a periductal lymphoplasmacytic infiltrate and storiform fibrosis, though to a lesser extent than LPSP. In fact, in the concordance study, many pathologists could not distinguish LPSP from IDCP. Finally, IDCP is also steroid responsive. Many experts believed therefore that IDCP may be an organ (pancreas)-specific autoimmune disorder. However, the occurrence of neutrophils infiltrating some ducts and acini so far remains unexplained by an autoimmune mechanism.
At least some experts believe that the overlap between the 2 forms of AIP is further confounded by the fact that IDCP and LPSP may not always be distinguishable using current diagnostic criteria. For example, both can fulfill Japanese and Asian diagnostic criteria for AIP based on imaging criteria and biopsy showing lymphoplasmacytic infiltrate with fibrosis, histologic features common to both LPSP and IDCP. Similarly, with the Italian criteria such patients would fulfill the criteria for AIP if they responded to steroids, as both forms of the disease do. Similarly, clinicians have used a steroid trial for the diagnosis of AIP using HISORt (histology, imaging features, serology, other organ involvement and response to steroid treatment) criteria, though collateral evidence of AIP in the form of raised serum IgG4 or other organ involvement (features of LPSP) is necessary before steroids are given. A case of AIP from Japan was presented which resembled IDCP with regard to the clinical profile (young, seronegative and associated with inflammatory bowel disease) but met the Japanese/Asian diagnostic criteria noted above. A histologically confirmed case of IDCP from Korea was presented whose imaging features resembled those seen in LPSP and which responded dramatically to steroids with normalization of imaging abnormalities.
The expert panel acknowledged that the current practice is to refer to both disease entities as AIP due to the inability to differentiate LPSP from IDCP without histology and review by an experienced pathologist. Therefore, there is a clear need to distinguish these entities nosologically to avoid continued confusion between them, to help provide prognostic information and to guide patient care. This would also provide the framework for future research in the field, including identification of specific biomarkers for both entities.
The European and American experts favored the continued inclusion of IDCP as a unique type of AIP due to [20] [21] [22] . Most, but not all present at the meeting agreed that this terminology best reflected our current state of knowledge. All agreed that as we learn more about both entities, the terminology would surely change. Summary: (1) Diagnostic criteria for AIP should recognize that there are 2 forms of the disease. This will allow further study of these entities and identification of specific markers for both forms of AIP.
(2) Currently, the disease associated with IDCP can be definitively diagnosed only by histologic examination. Use of a steroid trial does not distinguish the disease associated with LPSP from IDCP.
(3) While uniform consensus was not achieved, the majority of experts agreed that the clinical phenotypes associated with the histopathologic patterns of LPSP (AIP without GELs) and IDCP (AIP with GELs) should be referred to as type 1 and type 2 AIP, respectively.
